Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cambodia antimalarial efficacy study of dihydroartemisinin-piperaquine, atovaquone-proguanil, and chloroquine
ACTRN12612000184875Phase 4Completed
- Sponsor
- The Global Fund to Fight AIDS, Tuberculosis and Malaria
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dihydroartemisinin + piperaquine, atovaquone + proguanil and chloroquine in Malaria and malaria (3 arms), sponsored by The Global Fund to Fight AIDS, Tuberculosis and Malaria. Primary endpoints: 42-day adequate clinical and parasitological response for falciparum malaria, 42-day PCR-corrected adequate clinical and parasitological response for falciparum malaria and 1 more. Started Jul 2008; status: completed.
02
Drugs
dihydroartemisinin + piperaquineatovaquone + proguanilchloroquine
03
Conditions
Malariamalaria
Beyond the preview
Go deeper on ACTRN12612000184875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000184875.